Related references
Note: Only part of the references are listed.Keeping Nanomedicine on Target
Wei Zhang et al.
NANO LETTERS (2021)
Oral Delivery of Parathyroid Hormone Using a Triple-Padlock Nanocarrier for Osteoporosis via an Enterohepatic Circulation Pathway
Jeong Man An et al.
ACS APPLIED MATERIALS & INTERFACES (2021)
Activation of the GLP-1 receptor by a non-peptidic agonist
Peishen Zhao et al.
NATURE (2020)
Oral GLP1 Gene Delivery by an Antibody-Guided Nanomaterial to Treat Type 2 Diabetes Mellitus
Mohammad Nazmul Hasan et al.
ACS APPLIED MATERIALS & INTERFACES (2020)
Controlled release and targeting of polypeptide-deposited liposomes by enzymatic degradation
Yuuka Fukui et al.
POLYMER JOURNAL (2019)
Nanoscale systems for local drug delivery
Tianjiao Ji et al.
NANO TODAY (2019)
Oral Nonviral Gene Delivery for Chronic Protein Replacement Therapy
Po-Yen Lin et al.
ADVANCED SCIENCE (2018)
Oral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetes
Md Nurunnabi et al.
JOURNAL OF CONTROLLED RELEASE (2017)
One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer
Kelli M. Luginbuhl et al.
NATURE BIOMEDICAL ENGINEERING (2017)
Getting Drugs Across Biological Barriers
Rong Yang et al.
ADVANCED MATERIALS (2017)
Nanoparticles Made From Xyloglucan-Block-Polycaprolactone Copolymers: Safety Assessment for Drug Delivery
Leticia Mazzarino et al.
TOXICOLOGICAL SCIENCES (2015)
Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Malcolm A. Young et al.
POSTGRADUATE MEDICINE (2014)
Intracellular trafficking pathways involved in the gene transfer of nano-structured calcium phosphate-DNA particles
Dana Y. E. Olton et al.
BIOMATERIALS (2011)
Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
Wolfgang Glaesner et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IκBα/NF-κB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid
Prasenjit Manna et al.
FREE RADICAL BIOLOGY AND MEDICINE (2010)
Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development
Iftekhar Mahmood
ADVANCED DRUG DELIVERY REVIEWS (2007)
Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis
Young-Sun Lee et al.
DIABETES (2007)
Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation
Diana L. Williams et al.
DIABETES (2006)
Share Paper
